Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia. - Wikidata - awgldk - TriplyDB

Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.

Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.

http://www.wikidata.org/entity/Q31131682

about

Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.

P2860

Q39613942-A9F34B83-1A77-42F4-ABC2-EC48C54580B6 Q40131084-FE3F442B-91D0-4797-A5B6-B2F15BD2EA8F

P2860

Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.

http://www.wikidata.org/entity/Q31131682

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@ast

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@en

type

label

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@ast

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@en

prefLabel

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@ast

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@en

P1433

Q31131682-C4075614-2730-4EC7-BB87-2387ADEC50D6

P1476

Q31131682-900C32FF-D2B7-4925-BFB0-82A285E7E7C8

P2093

Q31131682-27A6A61D-6890-4F40-B9B2-2555E4B319A2

Q31131682-A0156FB6-99DD-4A89-A1B8-73AEECE0BBC4

Q31131682-A7FFD7D1-4234-40E2-8D88-064A9C781D07

Q31131682-BB865819-41EF-4646-8A12-A0ED633540AA

Q31131682-D609CE34-AD01-4E3A-932C-2C938572BA64

Q31131682-F7B6B2E7-B00F-491A-8A27-CB20594A09B8

P2860

Q31131682-05708C5E-ED69-4E49-A31C-660DAC2A2416

Q31131682-21E89AA8-C287-4D70-B913-C7DA569E2E06

Q31131682-304A0F0B-EE2F-408E-B684-B83B5354BC74

Q31131682-3B2F68DE-CBDC-4B20-8CC3-331420F97589

Q31131682-48884985-A1C6-46AD-80B2-7953B1E86605

Q31131682-51428640-BE4B-4FF3-AE68-3AE1F32B3789

Q31131682-63AB92BF-BFAF-4332-91A3-216D1A0B2F7B

Q31131682-69EA4F4A-97E6-4F08-949A-404645BC3F7C

Q31131682-6B7FC064-06C2-4B86-977F-C974A1578B9C

Q31131682-79548369-F215-4928-8380-D1E6DC59E7F9

P304

Q31131682-4750840D-7054-4D21-9E7C-4DD7E4B1483A

P31

Q31131682-601E2550-0CF9-4A4D-9C31-E2F51902561A

P356

Q31131682-659A094C-CC91-4563-9D22-3EB2A46BB8B4

P407

Q31131682-6F754F2A-74B7-4309-9E9E-30FADEAC7EB6

P433

Q31131682-2D1C266F-6383-4DF8-9133-E8E3AE9494CB

P478

Q31131682-E7D417FC-3415-4751-8197-5F50DA820E3B

P50

Q31131682-F1DF2F16-5582-438B-A28F-806F07DA3542

P577

Q31131682-1E796DA9-A3C5-496B-9891-AAB6E07365C8

P698

Q31131682-48F1CC8F-5E80-4D31-A5C3-D3A146505F03

P921

Q31131682-D72D486C-6D55-4187-A76C-468A9E5B5514

Q31131682-E3E9448F-D48E-4F7C-8015-6F194FED60C4

P932

Q31131682-482D7197-C466-4156-9565-97C997C8C29B

P356

JOURNAL.PONE.0163271

P1433

P1476

Carbapenem Breakpoints for Aci ...... from Patients with Bacteremia.

@en

P2093

I-Hsin Lee

http://www.w3.org/2001/XMLSchema#string

Mei-Chun Chiang

http://www.w3.org/2001/XMLSchema#string

Te-Li Chen

http://www.w3.org/2001/XMLSchema#string

Ya-Sung Yang

http://www.w3.org/2001/XMLSchema#string

Yi-Tzu Lee

http://www.w3.org/2001/XMLSchema#string

Yung-Chih Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region.

Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation

Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan

Acinetobacter baumannii: emergence of a successful pathogen

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Setting and revising antibacterial susceptibility breakpoints.

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.

Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations.

P304

e0163271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0163271

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27644087

http://www.w3.org/2001/XMLSchema#string

P921

Acinetobacter baumannii

carbapenem antibiotic

P932

5028070

http://www.w3.org/2001/XMLSchema#string